ArticleJournal of agricultural and food chemistry2013
Nanoencapsulation enhances epigallocatechin-3-gallate stability and its antiatherogenic bioactivities in macrophages.
Article in Journal of agricultural and food chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 96 citations in OpenAlex.
- EGCG targeting autophagy in cardiovascular diseases: mechanisms and therapeutic potential.Molecular biology reports · 2026Review
- Nanodelivery of Bioactive Natural Products: A Targeted Therapeutic Breakthrough for Atherosclerosis.Pharmaceutics · 2025Review
- Lipid-Based Nanotechnologies for Delivery of Green Tea Catechins: Advances, Challenges, and Therapeutic Potential.Pharmaceutics · 2025Review
- Potentiation and in vivo evaluation of anti-obesity activity of berberine through encapsulation in guar-acacia gum nanocomplexes.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- The Dual Role of Dietary Phytochemicals in Oxidative Stress: Implications for Oncogenesis, Cancer Chemoprevention, and ncRNA Regulation.Antioxidants (Basel, Switzerland) · 2025Review
- The green tea component (-)-epigallocatechin-3-gallate protects against cytokine-induced epithelial barrier damage in intestinal epithelial cells.Frontiers in pharmacology · 2025Article
- Anti-cancer Properties of Epigallocatechin-3-gallate (EGCG) and its Signaling Pathways.Current medicinal chemistry · 2025Review
- Advances in the treatment of atherosclerosis with ligand-modified nanocarriers.Exploration (Beijing, China) · 2024Review
- Lipid-Based Nanoparticles in Delivering Bioactive Compounds for Improving Therapeutic Efficacy.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Biomaterials-Based Antioxidant Strategies for the Treatment of Oxidative Stress Diseases.Biomimetics (Basel, Switzerland) · 2024Review
- The Commonly Used Stabilizers for Phytochemical-Based Nanoparticles: Stabilization Effects, Mechanisms, and Applications.Nutrients · 2023Review
- Alzheimer's Disease and Green Tea: Epigallocatechin-3-Gallate as a Modulator of Inflammation and Oxidative Stress.Antioxidants (Basel, Switzerland) · 2023Review
- A comprehensive review of nano-delivery system for tea polyphenols: Construction, applications, and challenges.Food chemistry: X · 2023Review
- Modulating Inflammation-Mediated Diseases via Natural Phenolic Compounds Loaded in Nanocarrier Systems.Pharmaceutics · 2023Review
- The Anticancer Potential of Plant-Derived Nutraceuticals via the Modulation of Gene Expression.Plants (Basel, Switzerland) · 2022Review
- Epigallocatechin-3-gallate: A phytochemical as a promising drug candidate for the treatment of Parkinson's disease.Frontiers in pharmacology · 2022Review
- Advances in Nanodelivery of Green Tea Catechins to Enhance the Anticancer Activity.Molecules (Basel, Switzerland) · 2021Review
- Applications of Catechins in the Treatment of Bacterial Infections.Pathogens (Basel, Switzerland) · 2021Review
- Preparation and Evaluation of a Self-Nanoemulsifying Drug Delivery System Loaded with Heparin Phospholipid Complex.International journal of molecular sciences · 2021Article
- Current Advances in the Use of Nanophytomedicine Therapies for Human Cardiovascular Diseases.International journal of nanomedicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
We have successfully synthesized (-)-epigallocatechin-3-gallate (EGCG) encapsulated nanostructured lipid carriers (NLCE) and chitosan-coated NLCE (CSNLCE) using natural lipids, surfactant, chitosan, and EGCG. Nanoencapsulation dramatically improved EGCG stability. CSNLCE significantly increased EGCG content in THP-1-derived macrophages compared with nonencapsulated EGCG. As compared to 10 μM nonencapsulated EGCG, both NLCE and CSNLCE at the same concentration significantly decreased macrophage cholesteryl ester content. NLCE and CSNLCE significantly decreased mRNA levels and protein secretion of monocyte chemoattractant protein-1 (MCP-1) levels in macrophages, respectively. These data suggest that nanoencapsulated EGCG may have a potential to inhibit atherosclerotic lesion development through decreasing macrophage cholesterol content and MCP-1 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.